- Home
- AGIO vs SKE Comparison
AGIO vs SKE Comparison
Compare AGIO & SKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- SKE
- Stock Information
- Founded
- AGIO 2007
- SKE 1979
- Country
- AGIO United States
- SKE Canada
- Employees
- AGIO N/A
- SKE N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- SKE Precious Metals
- Sector
- AGIO Health Care
- SKE Basic Materials
- Exchange
- AGIO Nasdaq
- SKE Nasdaq
- Market Cap
- AGIO 2.1B
- SKE 2.0B
- IPO Year
- AGIO 2013
- SKE N/A
- Fundamental
- Price
- AGIO $36.39
- SKE $18.90
- Analyst Decision
- AGIO Buy
- SKE
- Analyst Count
- AGIO 6
- SKE 0
- Target Price
- AGIO $57.00
- SKE N/A
- AVG Volume (30 Days)
- AGIO 771.2K
- SKE 464.2K
- Earning Date
- AGIO 10-30-2025
- SKE 11-13-2025
- Dividend Yield
- AGIO N/A
- SKE N/A
- EPS Growth
- AGIO N/A
- SKE N/A
- EPS
- AGIO 11.13
- SKE N/A
- Revenue
- AGIO $40,875,000.00
- SKE N/A
- Revenue This Year
- AGIO $28.19
- SKE N/A
- Revenue Next Year
- AGIO $152.14
- SKE N/A
- P/E Ratio
- AGIO $3.27
- SKE N/A
- Revenue Growth
- AGIO 30.57
- SKE N/A
- 52 Week Low
- AGIO $23.42
- SKE $7.32
- 52 Week High
- AGIO $62.58
- SKE $18.74
- Technical
- Relative Strength Index (RSI)
- AGIO 51.16
- SKE 72.15
- Support Level
- AGIO N/A
- SKE $17.33
- Resistance Level
- AGIO $37.18
- SKE $17.97
- Average True Range (ATR)
- AGIO 1.43
- SKE 0.63
- MACD
- AGIO -1.50
- SKE 0.20
- Stochastic Oscillator
- AGIO 88.53
- SKE 89.92
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.